Medwin Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.95 M
- Company Age 15 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.80 Cr
- Satisfied Charges ₹ 3.40 M
- Revenue Growth 12.57%
- Profit Growth 66.81%
- Ebitda -5.73%
- Net Worth 12.23%
- Total Assets 7.10%
About Medwin Pharmaceuticals
Medwin Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 June 2009 and has a history of 15 years and eight months. Its registered office is in Aligarh, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.95 M.
The company currently has active open charges totaling ₹1.80 Cr. The company has closed loans amounting to ₹3.40 M, as per Ministry of Corporate Affairs (MCA) records.
Manish Bhargava and Nibha Bhargava serve as directors at the Company.
Company Details
- Location
Aligarh, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33111UP2009PTC037614
- Company No.
037614
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jun 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Medwin Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nibha Bhargava  | Director | 17-Jun-2009 | Current |
| Manish Bhargava | Director | 17-Jun-2009 | Current |
Financial Performance of Medwin Pharmaceuticals.
Medwin Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 12.57% increase. The company also saw a substantial improvement in profitability, with a 66.81% increase in profit. The company's net worth Soared by an impressive increase of 12.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medwin Pharmaceuticals?
In 2021, Medwin Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹18.00 M
₹3.40 M
Charges Breakdown by Lending Institutions
- Yes Bank Limited : 1.80 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Jul 2021 | Yes Bank Limited | ₹1.80 Cr | Open |
| 28 Nov 2014 | Canara Bank | ₹3.40 M | Satisfied |
How Many Employees Work at Medwin Pharmaceuticals?
Medwin Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medwin Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medwin Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.